Clinical trials: Type 2 Diabetes Mellitus 1
Weight Management
Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)
The goal of this clinical study is to learn more about the study drug, GS-4571, and how safe it is in 3 groups, i) Healthy participants, ii) Healthy non-diabetic obese participants, and iii) Non-obese participants with Type 2…
- Trial name
- NCT06562907
- Testing
- GS-4571, Omeprazole
- Where
- 3 sites in United States
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Type 2 Diabetes Mellitus
Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus
This is a Phase 1, randomized, placebo-controlled, double-blind (investigator- and participant-blinded), sponsor-open study of PF-07081532.
- Trial name
- NCT05158244
- Testing
- PF-07081532
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Pfizer
Type 1 Diabetes
Genome-wide Association Study of Different Types of Diabetes and Construction of Genetic Risk Score
To enhance the genetic profile of T1D patients in China and construct a Chinese-specific GRS and evaluated its ability to differentiate between T1D and controls, as well as between T1D and T2D.
- Trial name
- NCT06791330
- Volunteers
- 7,000 people
- Sponsor
- Second Xiangya Hospital of Central South University
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Assessment of Mealtime Bolus Insulin Behavior
The main purpose of this study is to estimate missed bolus insulin doses in diabetics. This is a 12-week, single-arm, outpatient, exploratory study with two study periods in Type 1 or Type 2 diabetics, with an investigational…
- Trial name
- NCT03368807
- Testing
- Continuous Glucose Monitoring, Insulin Lispro
- Where
- 6 sites in United States
- Volunteers
- 79 people
- Sponsor
- Eli Lilly and Company
Diabetes, Type 1 Diabetes
The Role of South Asian vs European Origins on Circulating Regenerative Cell Exhaustion
ORIGINS-RCE is an observational, cross-sectional, two-arm study aimed at determining if an individual's ethnic origin influences the number of blood vessel-forming stem cells in the bloodstream.
- Conditions
- Diabetes, Type 1 Diabetes, Type 2 Diabetes, Ischemic Heart Disease
- Trial name
- ORIGINS-RCE (NCT05253521)
- Where
- 3 sites in Canada
- Volunteers
- 120 people
- Sponsor
- Canadian Medical and Surgical Knowledge Translation Research Group
Hypoglycemia, Diabetes Mellitus, Type 2
Investigating Novel Predictions of Hypoglycemia Occurrence in Real-world Models
Hypoglycemia is the most common diabetes-related adverse event. However, it is often under-reported to healthcare providers by patients and simultaneously, not often asked about by healthcare providers.
- Conditions
- Hypoglycemia, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
- Trial name
- iNPHORM (NCT04219514)
- Where
- United States
- Volunteers
- 1,206 people
- Sponsor
- Stewart Harris
Type 1 Diabetes Mellitus
BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes
To obtain safety and tolerability information in patients with type 1 diabetes where Dapagliflozin is added on to Insulin (for 14 days)
- Trial name
- NCT01498185
- Testing
- Dapagliflozin
- Where
- 12 sites in United States
- Volunteers
- 171 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Diabetes Mellitus, Type 2
Green Digital Diabetes Waste Project
The purpose of this study is to determine how people with diabetes are disposing of various products and devices and at what rates so that better devices with less waste can be designed in the future.
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
- Trial name
- NCT06071325
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- Florida State University
Type 2 Diabetes Mellitus
Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus
In this randomized, double-blind, double-dummy, placebo-controlled study, approximately 675 eligible subjects with type 2 diabetes and inadequate control on at least one and up to 3 oral glucose-lowering agents will undergo an…
- Trial name
- NCT04606576
- Testing
- ORMD-0801 QD, ORMD-0801 BD
- Where
- United States
- Volunteers
- 710 people
- Sponsor
- Oramed, Ltd.
Diabete Mellitus, Medical Device
Non-invasive Glucose Measurement With Raman Technology in Patients With Type 1 and Type 2 Diabetes
The study was established to collect data and reference measurements in order to establish calibration models for the Prototype 0.3
- Trial name
- NCT03781232
- Testing
- Prototype 0.3
- Where
- 2 sites in Germany
- Volunteers
- 47 people
- Sponsor
- RSP Systems A/S
Diabetes Mellitus, Type 2
Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 Diabetes
This is a trial in subjects with Type 2 diabetes mellitus to study the safety, tolerability and pharmacokinetics of multiple ascending doses of PF-05231023.
- Trial name
- NCT01396187
- Testing
- PF-05231023
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Pfizer
Spinal Cord Injuries, Type 2 Diabetes
Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes
It is not known whether a new diabetes drug, semaglutide, is an effective treatment for type 2 diabetes for persons with spinal cord injury (SCI), a population at higher risk for this condition.
- Trial name
- NCT06706284
- Testing
- Semaglutide Injectable Product
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Marzieh Salehi
Type 1 Diabetes
Efficacy and Safety of Sorafenib in New-Onset Type 1 Diabetes Mellitus
The purpose of this study is to investigate the therapeutic effect and safety of Sorafenib in T1DM patients.
- Trial name
- NCT06227221
- Testing
- Sorafenib
- Volunteers
- 10 people
- Sponsor
- Second Xiangya Hospital of Central South University
Diabetic Retinopathy
Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study
This study is to test whether or not 32 milligrams (mg) of ruboxistaurin a day over three years will reduce vision loss associated with diabetic retinopathy.
- Trial name
- NCT00604383
- Testing
- ruboxistaurin
- Where
- United States
- Volunteers
- 685 people
- Sponsor
- Chromaderm, Inc.
Type 2 Diabetes Mellitus
Glucolipotoxicity and Type 2 Diabetes
Elevations of blood glucose and lipid are thought to be deleterious to the insulin secretory function of the pancreas. This is known as glucolipotoxicity. However, few studies have examined this in detail.
- Trial name
- NCT01375270
- Testing
- Glucotoxicity, Lipotoxicity
- Where
- Denmark
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Type 2 Diabetes
A Study of LY3549492 in Chinese Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to investigate LY3549492 in Chinese participants with type 2 diabetes. Participation in the study will last about 18 weeks.
- Trial name
- NCT07073170
- Testing
- LY3549492
- Where
- 3 sites in China
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Dyslipidemia, Type 2 Diabetes Mellitus
A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between YHR1705 and YHR1706
This is a phase 1, open label, multiple-dose, crossover clinical trial to investigate the pharmacokinetic drug interaction between YHR1705 and YHR1706 in healty male volunteers
- Trial name
- NCT03235362
- Testing
- YHR1705, YHR1706, YHR1705+YHR1706
- Where
- South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Type 2 Diabetes, Obesity
Splanchnic Blood Redistribution After Incretin Hormone Infusion and Obesity Surgery
Obesity is a worldwide problem and leads to multiple metabolic and endocrinological problems. Bariatric surgeries are a growing field as a treatment choice for morbid obesity (BMI > 35 kg/m2).
- Trial name
- GIP-PET (NCT01880827)
- Testing
- Roux-en-Y, GIP-infusion, GLP-1
- Where
- Finland
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Turku University Hospital
Diabetes Mellitus, Type 2
Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (5 mg once daily) compared to placebo given for 24 weeks as add-on therapy to metformin in patients with type 2 diabetes…
- Trial name
- NCT00601250
- Testing
- linagliptin
- Where
- 82 sites in United States, Czechia and 8 more
- Volunteers
- 701 people
- Sponsor
- Boehringer Ingelheim
Diabetes, Diabetes Mellitus, Type 1
Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to evaluate the efficacy and safety of biphasic insulin aspart 30 in subjects with type 1 or type 2 diabetes.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01467323
- Testing
- biphasic insulin aspart, biphasic human insulin
- Where
- 37 sites in Austria, Germany and 3 more
- Volunteers
- 303 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.